GlassScriptPhysician profile
Dawn R Springer
NPI 1134129604
$43,265.63
in general payments reported to CMS, 2019-2025
42 companies · $5,071 in 2025
The $5,071 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $9,865 · 2023: $5,697 · 2024: $5,123 · 2025: $5,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,058 · Consulting Fee: $4,680 · Food and Beverage: $1,898 · Travel and Lodging: $179 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,058.00 |
| Consulting Fee | $4,680.00 |
| Food and Beverage | $1,898.06 |
| Travel and Lodging | $179.26 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36,470.91 | 2021-2025 | Opdivo, Eliquis |
| Celgene Corporation | $3,736.50 | 2022-2023 | Opdivo, Reblozyl |
| Beigene USA, INC. | $327.96 | 2021-2023 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $297.92 | 2021-2023 | Iclusig, Alunbrig, Ninlaro |
| Eisai INC. | $264.22 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $182.61 | 2021-2023 | Imbruvica |
| Boston Scientific Corporation | $143.72 | 2025 | Watchman |
| Merck Sharp & Dohme LLC | $126.26 | 2022-2023 | Keytruda, Reblozyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2024 | Xifaxan |
| Janssen Biotech, INC. | $119.84 | 2021-2024 | Rybrevant, Erleada |
| Lilly USA, LLC | $105.16 | 2022-2023 | Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $101.05 | 2022-2024 | |
| Daiichi Sankyo INC. | $98.02 | 2021-2023 | Enhertu |
| Incyte Corporation | $93.30 | 2021-2022 | |
| Abbvie INC. | $88.59 | 2021-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.